Joel Isaacson & Co’s Alaunos Therapeutics TCRT Stock Holding History

Joel Isaacson & Co’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-22	Closed	-$18K	–	486
2016 Q4	$18K	Hold	22	–	–	﹤0.01%	438
2016 Q3	$19K	Hold	22	–	–	﹤0.01%	469
2016 Q2	$18K	Hold	22	–	–	﹤0.01%	480
2016 Q1	$25K	Hold	22	–	–	0.01%	457
2015 Q4	$28K	Hold	22	–	–	0.01%	420
2015 Q3	$30K	Hold	22	–	–	0.01%	417
2015 Q2	$40K	Buy	+22	New	+$34.2K	0.01%	396

Other funds holding TCRT

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Joel Isaacson & Co's TCRT Position: Q1 2017 in Review

Joel Isaacson & Co sold out of Alaunos Therapeutics (TCRT) in Q1 2017, closing a stake of 22 shares — an estimated $18K sold.

Joel Isaacson & Co first reported a position in TCRT in Q2 2015 and held it in 7 quarters. The position peaked at $40K in Q2 2015. 124 funds tracked by Wall St. Rank hold TCRT as of Q1 2017.

Joel Isaacson & Co reported no remaining Alaunos Therapeutics position as of Q1 2017 after selling out during the quarter.
Joel Isaacson & Co sold 22 Alaunos Therapeutics shares in Q1 2017, an estimated $18K.
Joel Isaacson & Co first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 7 quarters.
Joel Isaacson & Co's Alaunos Therapeutics position peaked at $40K in Q2 2015.
124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.